Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18590507 | 1.00 | MAPT (0.42) | MAPTATMNPSR1ALDH1A1CYP1A2 | |
| SCHEMBL18590503 | 1.00 | MAPT (0.42) | MAPTATMNPSR1ALDH1A1CYP1A2 | |
| SCHEMBL18590508 | 1.00 | MAPT (0.42) | MAPTATMNPSR1ALDH1A1CYP1A2 | |
| SCHEMBL6482507 | 0.84 | SLC6A3 (0.45) | ALDH1A1LMNA | |
| SCHEMBL6482502 | 0.84 | SLC6A3 (0.45) | ALDH1A1LMNA | |
| SCHEMBL6482499 | 0.84 | SLC6A3 (0.45) | ALDH1A1LMNA | |
| SCHEMBL12525034 | 0.83 | ALDH1A1 (0.48) | MAPTNPSR1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1904591 | 0.83 | ALDH1A1 (0.48) | MAPTNPSR1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1901694 | 0.83 | ALDH1A1 (0.48) | MAPTNPSR1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL19559429 | 0.81 | KDM1A (0.47) | MAPTALDH1A1CYP3A4SMN1; SMN2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20180044290-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN SEIYAKU KK (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9822069-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | MAPT 3087/4885ATM 4814/4885NPSR1 34/4885 |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, FPR3 | MAPT 3087/4885ATM 4814/4885NPSR1 34/4885 |
| US-20180044290-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, FPR3 | MAPT 3087/4885ATM 4814/4885NPSR1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.